CureTech, Ltd.

Financings Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billi

Pfizer Inc. is relying on future growth of the prostate cancer therapy Xtandi (enzalutamide) to justify the $14bn price it will pay to buy Medivation Inc. , but two pipeline products and the po

Medivation Inc. has rejected a second, $1bn higher buyout offer from Sanofi , but the Xtandi (enzalutamide) developer and the French big pharma have agreed to negotiate confidentially, putting

Analysis provided by Informa Business Intelligence's BioMedTracker and MedDeviceTracker. For more reporting from the conference, visit "The Pink Sheet" DAILY. Day One J.P. Morgan Notebook